Clinical Trial Update: Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

Clinical trial update for lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) in Phase 3; the study was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adpkd
• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Lixivaptan (lixivaptan)

Snippet

Sponsor: Palladio Biosciences | Conditions: Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Status: TERMINATED | Results posted: 2023-02-06